FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955803684> ?p ?o ?g. }

• W2955803684 endingPage "756" @default.
• W2955803684 startingPage "745" @default.
• W2955803684 abstract "Background Previous studies have highlighted a relationship between reduction in rate of exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood eosinophil count in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial showed that once-daily single-inhaler triple therapy significantly reduced exacerbations versus dual therapies. Blood eosinophil counts and smoking status could be important modifiers of treatment response to ICS. We aimed to model these relationships and their interactions, including outcomes other than exacerbations. Methods IMPACT was a phase 3, randomised, double-blind, parallel-group, 52-week global study comparing once-daily single-inhaler triple therapy (fluticasone furoate–umeclidinium–vilanterol) with dual inhaled therapy (fluticasone furoate–vilanterol or umeclidinium–vilanterol). Eligible patients had moderate-to-very-severe COPD and at least one moderate or severe exacerbation in the previous year. We used fractional polynomials to model continuous blood eosinophil counts. We used negative binomial regression for numbers of moderate and severe exacerbations, severe exacerbations, and pneumonia. We modelled differences at week 52 in trough FEV1, St George's Respiratory Questionnaire (SGRQ) total score, and Transition Dyspnoea Index using repeated measurements mixed effect models. IMPACT was registered with ClinicalTrials.gov, number NCT02164513. Findings The magnitude of benefit of regimens containing ICS (fluticasone furoate–umeclidinium–vilanterol n=4151 and fluticasone furoate–vilanterol n=4134) in reducing rates of moderate and severe exacerbations increased in proportion with blood eosinophil count, compared with a non-ICS dual long-acting bronchodilator (umeclidinium–vilanterol n=2070). The moderate and severe exacerbation rate ratio for triple therapy versus umeclidinium–vilanterol was 0·88 (95% CI 0·74 to 1·04) at blood eosinophil count less than 90 cells per μL and 0·56 (0·47 to 0·66) at counts of 310 cells per μL or more; the corresponding rate ratio for fluticasone furoate–vilanterol versus umeclidinium–vilanterol was 1·09 (0·91 to 1·29) and 0·56 (0·47 to 0·66), respectively. Similar results were observed for FEV1, Transition Dyspnoea Index, and SGRQ total score; however, the relationship with FEV1 was less marked. At blood eosinophil counts less than 90 cells per μL and at counts of 310 cells per μL or more, the triple therapy versus umeclidinium–vilanterol treatment difference was 40 mL (95% CI 10 to 70) and 60 mL (20 to 100) for trough FEV1, −0·01 (–0·68 to 0·66) and 0·30 (–0·37 to 0·97) for Transition Dyspnoea Index score, and −0·01 (–1·81 to 1·78) and −2·78 (–4·64 to −0·92) for SGRQ total score, respectively. Smoking status modified the relationship between observed efficacy and blood eosinophil count for moderate or severe exacerbations, Transition Dyspnoea Index, and FEV1, with former smokers being more corticosteroid responsive at any eosinophil count than current smokers. Interpretation This analysis of the IMPACT trial shows that assessment of blood eosinophil count and smoking status has the potential to optimise ICS use in clinical practice in patients with COPD and a history of exacerbations. Funding GlaxoSmithKline. Previous studies have highlighted a relationship between reduction in rate of exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood eosinophil count in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial showed that once-daily single-inhaler triple therapy significantly reduced exacerbations versus dual therapies. Blood eosinophil counts and smoking status could be important modifiers of treatment response to ICS. We aimed to model these relationships and their interactions, including outcomes other than exacerbations. IMPACT was a phase 3, randomised, double-blind, parallel-group, 52-week global study comparing once-daily single-inhaler triple therapy (fluticasone furoate–umeclidinium–vilanterol) with dual inhaled therapy (fluticasone furoate–vilanterol or umeclidinium–vilanterol). Eligible patients had moderate-to-very-severe COPD and at least one moderate or severe exacerbation in the previous year. We used fractional polynomials to model continuous blood eosinophil counts. We used negative binomial regression for numbers of moderate and severe exacerbations, severe exacerbations, and pneumonia. We modelled differences at week 52 in trough FEV1, St George's Respiratory Questionnaire (SGRQ) total score, and Transition Dyspnoea Index using repeated measurements mixed effect models. IMPACT was registered with ClinicalTrials.gov, number NCT02164513. The magnitude of benefit of regimens containing ICS (fluticasone furoate–umeclidinium–vilanterol n=4151 and fluticasone furoate–vilanterol n=4134) in reducing rates of moderate and severe exacerbations increased in proportion with blood eosinophil count, compared with a non-ICS dual long-acting bronchodilator (umeclidinium–vilanterol n=2070). The moderate and severe exacerbation rate ratio for triple therapy versus umeclidinium–vilanterol was 0·88 (95% CI 0·74 to 1·04) at blood eosinophil count less than 90 cells per μL and 0·56 (0·47 to 0·66) at counts of 310 cells per μL or more; the corresponding rate ratio for fluticasone furoate–vilanterol versus umeclidinium–vilanterol was 1·09 (0·91 to 1·29) and 0·56 (0·47 to 0·66), respectively. Similar results were observed for FEV1, Transition Dyspnoea Index, and SGRQ total score; however, the relationship with FEV1 was less marked. At blood eosinophil counts less than 90 cells per μL and at counts of 310 cells per μL or more, the triple therapy versus umeclidinium–vilanterol treatment difference was 40 mL (95% CI 10 to 70) and 60 mL (20 to 100) for trough FEV1, −0·01 (–0·68 to 0·66) and 0·30 (–0·37 to 0·97) for Transition Dyspnoea Index score, and −0·01 (–1·81 to 1·78) and −2·78 (–4·64 to −0·92) for SGRQ total score, respectively. Smoking status modified the relationship between observed efficacy and blood eosinophil count for moderate or severe exacerbations, Transition Dyspnoea Index, and FEV1, with former smokers being more corticosteroid responsive at any eosinophil count than current smokers. This analysis of the IMPACT trial shows that assessment of blood eosinophil count and smoking status has the potential to optimise ICS use in clinical practice in patients with COPD and a history of exacerbations." @default.
• W2955803684 created "2019-07-12" @default.
• W2955803684 creator A5001192345 @default.
• W2955803684 creator A5003111166 @default.
• W2955803684 creator A5005167055 @default.
• W2955803684 creator A5007172600 @default.
• W2955803684 creator A5008203993 @default.
• W2955803684 creator A5009003396 @default.
• W2955803684 creator A5010434469 @default.
• W2955803684 creator A5013701801 @default.
• W2955803684 creator A5025358852 @default.
• W2955803684 creator A5030660777 @default.
• W2955803684 creator A5036734448 @default.
• W2955803684 creator A5038228413 @default.
• W2955803684 creator A5045141623 @default.
• W2955803684 creator A5046338978 @default.
• W2955803684 creator A5048374080 @default.
• W2955803684 creator A5068917661 @default.
• W2955803684 creator A5072648555 @default.
• W2955803684 creator A5082568705 @default.
• W2955803684 creator A5086584655 @default.
• W2955803684 date "2019-09-01" @default.
• W2955803684 modified "2023-10-11" @default.
• W2955803684 title "Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial" @default.
• W2955803684 cites W1577251139 @default.
• W2955803684 cites W1987881697 @default.
• W2955803684 cites W2001104945 @default.
• W2955803684 cites W2022564653 @default.
• W2955803684 cites W2036476615 @default.
• W2955803684 cites W2088797046 @default.
• W2955803684 cites W2095591678 @default.
• W2955803684 cites W2099088996 @default.
• W2955803684 cites W2111374619 @default.
• W2955803684 cites W2127104182 @default.
• W2955803684 cites W2146831425 @default.
• W2955803684 cites W2146877487 @default.
• W2955803684 cites W2165465489 @default.
• W2955803684 cites W2169401204 @default.
• W2955803684 cites W2172490363 @default.
• W2955803684 cites W2279631877 @default.
• W2955803684 cites W2365138737 @default.
• W2955803684 cites W2405194161 @default.
• W2955803684 cites W2415309826 @default.
• W2955803684 cites W2464026584 @default.
• W2955803684 cites W2468772595 @default.
• W2955803684 cites W2515655475 @default.
• W2955803684 cites W2595161845 @default.
• W2955803684 cites W2604577460 @default.
• W2955803684 cites W2613974366 @default.
• W2955803684 cites W2746473595 @default.
• W2955803684 cites W2783705291 @default.
• W2955803684 cites W2785999277 @default.
• W2955803684 cites W2787684361 @default.
• W2955803684 cites W2802221596 @default.
• W2955803684 cites W2891482814 @default.
• W2955803684 cites W2897466202 @default.
• W2955803684 doi "https://doi.org/10.1016/s2213-2600(19)30190-0" @default.
• W2955803684 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31281061" @default.
• W2955803684 hasPublicationYear "2019" @default.
• W2955803684 type Work @default.
• W2955803684 sameAs 2955803684 @default.
• W2955803684 citedByCount "144" @default.
• W2955803684 countsByYear W29558036842019 @default.
• W2955803684 countsByYear W29558036842020 @default.
• W2955803684 countsByYear W29558036842021 @default.
• W2955803684 countsByYear W29558036842022 @default.
• W2955803684 countsByYear W29558036842023 @default.
• W2955803684 crossrefType "journal-article" @default.
• W2955803684 hasAuthorship W2955803684A5001192345 @default.
• W2955803684 hasAuthorship W2955803684A5003111166 @default.
• W2955803684 hasAuthorship W2955803684A5005167055 @default.
• W2955803684 hasAuthorship W2955803684A5007172600 @default.
• W2955803684 hasAuthorship W2955803684A5008203993 @default.
• W2955803684 hasAuthorship W2955803684A5009003396 @default.
• W2955803684 hasAuthorship W2955803684A5010434469 @default.
• W2955803684 hasAuthorship W2955803684A5013701801 @default.
• W2955803684 hasAuthorship W2955803684A5025358852 @default.
• W2955803684 hasAuthorship W2955803684A5030660777 @default.
• W2955803684 hasAuthorship W2955803684A5036734448 @default.
• W2955803684 hasAuthorship W2955803684A5038228413 @default.
• W2955803684 hasAuthorship W2955803684A5045141623 @default.
• W2955803684 hasAuthorship W2955803684A5046338978 @default.
• W2955803684 hasAuthorship W2955803684A5048374080 @default.
• W2955803684 hasAuthorship W2955803684A5068917661 @default.
• W2955803684 hasAuthorship W2955803684A5072648555 @default.
• W2955803684 hasAuthorship W2955803684A5082568705 @default.
• W2955803684 hasAuthorship W2955803684A5086584655 @default.
• W2955803684 hasConcept C126322002 @default.
• W2955803684 hasConcept C2776042228 @default.
• W2955803684 hasConcept C2776780178 @default.
• W2955803684 hasConcept C2777014857 @default.
• W2955803684 hasConcept C2779028295 @default.
• W2955803684 hasConcept C2780261241 @default.
• W2955803684 hasConcept C2780667556 @default.
• W2955803684 hasConcept C71924100 @default.
• W2955803684 hasConceptScore W2955803684C126322002 @default.
• W2955803684 hasConceptScore W2955803684C2776042228 @default.
• W2955803684 hasConceptScore W2955803684C2776780178 @default.

• next